Venia Legendi for Immunology, University of Heidelberg, Faculty of Medicine, Heidelberg, Germany, mentor Prof. Stefan Meuer, Heidelberg, Germany
Scientific Vita
Publications
Contact
Prof. Dr.
Adelheid Cerwenka
Academic Education and University Degrees
2007
1991 - 1995
PhD, Institute of Immunology, University of Vienna, Austria, supervised by Prof. Walter Knapp
1986 - 1991
Diploma in Pharmacy, Institute of Immunology, University of Vienna, Austria
Employment
2017 - today
Full Professor of Immunbiochemistry, Heidelberg University, Medical Faculty Mannheim, Germany
2003 - 2017
Head of Boveri Junior Group “Innate Immunity” at the German Cancer Research Center, Heidelberg, Germany
2001 - 2003
Head of Laboratory, Division of Autoimmune Diseases, Novartis Research Institute, Vienna, Austria
1998 - 2001
Post-doc, DNAX Research Institute and University of California, San Francisco, USA, with Prof. Lewis L. Lanier
1996 -1998
Post-doc, University of California, San Diego, CA, USA and at the Trudeau Institute, NY, USA, with Prof. Richard W. Dutton
Stojanovic A, Cerwenka A. 2018. Checkpoint inhibition: NK cells enter the scene. Nat Immunol. 19(7):650-652. Correia MP, Stojanovic A, Bauer K, Juraeva D, Tykocinski LO, Lorenz HM, Brors B, Cerwenka A. 2018. Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proc. Natl. Acad. Sci. (USA). 115(26):E5980-E5989. Cerwenka A, Lanier LL. 2018. Natural killers join the fight against cancer. Science. 359(6383):1460-1461. Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, Lasitschka F, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, Cerwenka A. 2018. Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis. J Hepatol. 68(3):421-430. Cerwenka A, Lanier LL. 2016. NK cell memory in viral infection, inflammation and cancer, Nature Immunology Reviews. 16(2):112-23. Rölle A, Pollmann J, Ewen EM, Le VT, Halenius A, Hengel H, Cerwenka A. 2014. IL-12 producing monocytes and HLA-E drive NKG2C+ NK cell expansion. J. Clin. Invest. 124(12):5305-16. Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A. 2013. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood. 122(5):684-693. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. 2012. Sustained effector function of IL-12/15/18 preactivated NK cells against established tumors. J Exp Med. 209(13):2351-65. Cerwenka A, Baron JL, and Lanier LL. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits NK cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. (USA). 98(20):11521-6.Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 12(6): 721-727.
- Address
- Office: Tridomus, Haus C, Ebene 5
Ludolf-Krehl-Strasse 13 - 17
Lab: Tridomus, Haus B, Ebene 3
Ludolf-Krehl-Strasse 7 - 11
D-68167 Mannheim - Adelheid.Cerwenka@medma.uni-heidelberg.de